Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment

Journal of Psychiatry and Neuroscience

Volumn 32, Issue 5, 2007, Pages 331-338

  Procyshyn, Ric M ^a,b   Wasan, Kishor M ^b   Thornton, Allen E ^c   Barr, Alasdair M ^b   Chen, Eric Y H ^f   Pomarol Clotet, Edith ^g   Stip, Emmanuel ^e   Williams, Richard ^b   MacEwan, G William ^b   Birmingham, C Laird ^b,d   Honer, William G ^a,b  

^a RIVERVIEW HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cholesterol; Clozapine; Lipids; Triglycerides

Indexed keywords

CLOZAPINE; PLACEBO; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 34848827473     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Vampini C, Steinmayr M, Bilone F. The increase of plasma levels of triglyceride during clozapine treatment: a case report [abstract]. Neuropsychopharmacology 1994;10:249s.
2. Ghaeli P, Dufresne RI. Elevated serum triglycerides on clozapine resolve with risperidone [abstract]. Pharmacotherapy 1995;15:382-3.
3. Gaulin BD, Markowitz JS, Caley DF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-2.
4. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999;22:98-101.
5. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-81.
6. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-65.
7. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64:598-604.
8. Dursun SM, Szemis A, Andrews H, et al. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999;24:453-5.
9. Baymiller SP, Ball P, McMahon RP, et al. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003;59:49-57.
10. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982;34:715-8.
11. Brajtburg J, Elberg S, Boland J, et al. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 1984;149:986-92.
12. Brunner LJ, Vadiei K, Luke DR. Cyclosporine disposition in the hyperlipidemic rat model. Res Commun Chem Pathol Pharmacol 1988;59:339-48.
13. Wasan KM. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J Pharmacol Toxicol Methods 1996;36:1-11.
14. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
15. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-90.
16. Bai YM, Lin CC, Chen JY, et al. Weight gain among patients on clozapine [letter], Psychiatr Serv 1999;50:704-5.
17. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-51.
18. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003;59:19-27.
19. Durrington PN. Biological variation in serum lipid concentrations. Scand J Clin Lab Invest Suppl 1990;198:86-91.
20. Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-1 and B. Clin Chem 1994;40:574-8.
21. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82.
22. Wasan KM, Ramaswamy M, Haley J, et al. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer. J Pharm Sci 1997;86:876-9.
23. Demacker PN, Hijmans AG, Brenninkmeijer BJ, et al. Five methods for determining low-density lipoprotein cholesterol compared. Clin Chem 1984;30:1797-800.
24. Ascher-Svanum H, Stensland MD, Kinon BJ, et al. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 2005;19(6 Suppl);110-7.
25. Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005;5:3. Available: www.biomedcentral.com/ 1471-244X/5/3 (accessed 2006 March 29).
26. Pande S, Procyshyn RM, Nazerali M, et al. Do triglycerides modulate the effectiveness of clozapine? Int Clin Psychopharmacol 2002;17:197-9.
27. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986;32:142-5.
28. Tonolo G, Ciccarese M, Brizzi P, et al. Cyclical variation of plasma lipids, apolipoproteins, and lipoprotein(a) during menstrual cycle of normal women. Am J Physiol 1995;269:E1101-5.
29. O'Hanesian MA, Rosner B, Bishop LM, et al. Effects of inherent responsiveness to diet and day-to-day diet variation on plasma lipoprotein concentrations. Am J Clin Nutr 1996;64:53-9.
30. Pereira MA, Weggemans RM, Jacobs DR, et al. Within-person variation in serum lipids: implications for clinical trials. Int J Epidemiol 2004;33:534-41.
31. Smith SJ, Cooper GR, Myers GL, et al. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem 1993;39:1012-22.
32. Hawthon K, Cowen P, Owens D, et al. Low serum cholesterol and suicide. Br J Psychiatry 1993;162:818-25.
33. Dursun SM, Reveley MA. Low serum cholesterol and serotonin receptor subtypes. [Letter]. Br J Psychiatry 1993;163:417-8.
34. Boston PF, Dursun SM, Zafar R, et al. Serum cholesterol and treatment-resistance in schizophrenia. Biol Psychiatry 1996;40:542-3.
35. Boston PF, Dursun SM, Reveley MA. Cholesterol and mental disorder. Br J Psychiatry 1996;169:682-9.
36. Procyshyn RM, Kennedy NB, Marriage S, et al. Plasma protein and lipoprotein distribution of clozapine. Am J Psychiatry 2001;158:949-51.
37. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-73.
38. Machard B, Missline P, Lemaire M. Influence of plasma protein binding on the brain re-uptake of an antifungal agent, terbinafine, in rats. J Pharm Pharmacol 1989;41:700-4.